Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PREPARE-2)

This Phase I interventional trial (n=50) will study the pharmacokinetics (how the drug moves through the body) and pharmacodynamics (the drug’s effects on the body) of ketamine in postpartum women following a caesarean delivery. Participants will receive a ketamine infusion (12.6mg/70kg/hr for 1 hour, followed by 3.5mg/70kg/hr for 11 hours) to assess how the drug is metabolised and its potential role in managing post-surgical pain and postpartum depression.

The study, led by Dr Grace Lim at the University of Pittsburgh, will also compare ketamine metabolism in postpartum women to that of non-pregnant female and male controls receiving the same dosing protocol. This research aims to address gaps in understanding ketamine’s effectiveness and metabolism in postpartum pain management and mood regulation. Outcomes will include measuring ketamine concentration in blood samples, assessing patient-reported side effects, and evaluating pain and depression scores over 12 weeks.

Topic Postpartum Depression Depression Healthy Subjects
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

National Institute of Mental Health
This company doesn't have a full profile yet, it is linked to a clinical trial.

University of Pittsburgh
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.